Search results
Results from the WOW.Com Content Network
Pages in category "Drugs developed by AstraZeneca" The following 133 pages are in this category, out of 133 total. This list may not reflect recent changes. A.
Non-small cell lung cancer and pancreatic cancer. Skin reactions, diarrhoea, GI bleeds, anaemia, dehydration, interstitial lung disease (uncommon), hepatic failure (rare), hepatorenal syndrome (rare), GI perforation (rare) and ulcerative keratitis (rare). Gefitinib: PO: EGFR inhibitor. EGFR-mutation positive non-small cell lung cancer.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
The U.S. Food and Drug Administration first approved the drug in 2017 to treat a type of bladder cancer. Imfinzi won approval for use in mid-stage non-small cell lung cancer a year later.
The trial compared the two treatments -- AstraZeneca's drug and chemotherapy -- of patients whose non-small cell lung cancer had returned after one or two prior treatment attempts.
AstraZeneca's application was based on positive late-stage data that showed the drug improved overall survival and progression-free survival in patients with a type of lung cancer, whose disease ...
Sintilimab (IBI308), a human anti-PD-1 antibody developed by Innovent and Eli Lilly for patients with non-small cell lung cancer . [27] INCMGA00012 (MGA012) is a humanized IgG4 monoclonal antibody developed by Incyte and MacroGenics. [28] AMP-224 by AstraZeneca/MedImmune and GlaxoSmithKline [29] AMP-514 (MEDI0680) by AstraZeneca [30]
Monday, AstraZeneca Plc (NASDAQ:AZN) shared detailed results from the TROPION-Lung01 Phase 3 of datopotamab deruxtecan (Dato-DXd) compared to docetaxel, the current standard of care chemotherapy ...